Clinical trials | Diseases | Responses | References |
---|
Phase I | R/R CLL | ORR—79 % |
81, 83
|
Phase Ia | R/R NHL | ORR—48 % |
84
|
Phase II | R/R AML | ORR—15 % |
85
|
New AML |
-
R/R relapsed/refractory, ORR overall response rate, CLL chronic lymphoid leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia